A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer

Rodriguez Cristina P.; Wu Qian (Vicky); Voutsinas Jenna; Fromm Jonathan R.; Jiang Xiuyun; Pillarisetty Venu G.; Lee Sylvia M.; Santana-Davila Rafael; Goulart Bernardo; Baik Christina S.; Chow Laura Q. M.; Eaton Keith; Martins Renato

首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer

【24h】

A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer

机译：彭布罗鲁瑞司和副转移头和颈鳞状细胞癌和唾液腺癌中的II期试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: This clinical trial combined pembrolizumab and vorinostat in recurrent/metastatic squamous cell carcinomas of the head and neck (HN), and salivary gland cancer (SGC).

机译：目的：该临床试验组合Pembrolizumab和Vorinostat在头部和颈部（HN）的复发/转移性鳞状细胞癌中，唾液腺癌（SGC）。

著录项

来源
《Clinical cancer research: an official journal of the American Association for Cancer Research》 |2020年第4期|共9页
作者
Rodriguez Cristina P.; Wu Qian (Vicky); Voutsinas Jenna; Fromm Jonathan R.; Jiang Xiuyun; Pillarisetty Venu G.; Lee Sylvia M.; Santana-Davila Rafael; Goulart Bernardo; Baik Christina S.; Chow Laura Q. M.; Eaton Keith; Martins Renato;
展开▼
作者单位

Univ Washington Dept Med Div Oncol Seattle WA 98109 USA;

Fred Hutchinson Canc Res Ctr Publ Hlth Sci Div 1124 Columbia St Seattle WA 98104 USA;

Fred Hutchinson Canc Res Ctr Publ Hlth Sci Div 1124 Columbia St Seattle WA 98104 USA;

Univ Washington Dept Lab Med Seattle WA 98109 USA;

Univ Washington Dept Surg Seattle WA 98109 USA;

Univ Washington Dept Surg Seattle WA 98109 USA;

Univ Washington Dept Med Div Oncol Seattle WA 98109 USA;

Univ Washington Dept Med Div Oncol Seattle WA 98109 USA;

Univ Washington Dept Med Div Oncol Seattle WA 98109 USA;

Univ Washington Dept Med Div Oncol Seattle WA 98109 USA;

Univ Washington Dept Med Div Oncol Seattle WA 98109 USA;

Univ Washington Dept Med Div Oncol Seattle WA 98109 USA;

Univ Washington Dept Med Div Oncol Seattle WA 98109 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 来自一项艾日布林联合吉西他滨对比紫杉醇联合吉西他滨作为HER2阴性转移性乳腺癌的一线化疗的II期、多中心、随机试验的包含神经病变相关量表的生活质量结果:韩国癌症研究组试验(KCSG BR13-11) [J] . Ji-Yeon Kim, Young-Hyuck Im, Tae-Yong Kim, 癌症（英文版） . 2019,第008期
2. A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer [J] . Rodriguez Cristina P., Wu Qian (Vicky), Voutsinas Jenna, Clinical cancer research: an official journal of the American Association for Cancer Research . 2020,第4期

机译：彭布罗鲁瑞司和副转移头和颈鳞状细胞癌和唾液腺癌中的II期试验
3. Final Analysis of the pivotal Phase III Study KEYNOTE-048 Improved Overall Survival of Patients on Pembrolizumab (KEYTRUDA (R)) in First-Line Treatment of recurrent or metastatic Squamous Cell Carcinoma of the Head and Neck Region [J] . Oncology research and treatment. . 2019,第7a8期

机译：枢转期III研究的最终分析keynote-048在头部和颈部的复发或转移性鳞状细胞癌的一线治疗中提高了Pembrolizumab（Keytruda（R））的患者的整体存活
4. Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy [J] . Jean-Pascal H Machiels, Lisa F Licitra, Robert I Haddad, BMC Cancer . 2014,第1期

机译：LUX-Head＆Neck的原理和设计1：阿法替尼与甲氨蝶呤在铂类药物治疗后复发和/或转移性头颈部鳞状细胞癌患者中进行的一项随机，III期临床试验
5. Adenylyl Cyclase-Associated Protein 1 in Metastasis of Squamous Cell Carcinoma of the Head and Neck and Non-Small Cell Lung Cancer [C] . G. V. Kakurina, E. S. Kolegova, O. V. Cheremisina, International Conference on Physics of Cancer . 2016

机译：腺苷酸环酶相关蛋白1在头部和颈部和非小细胞肺癌的鳞状细胞癌转移中
6. Inflammatory mechanisms of chemokine receptor 7 expression in metastatic squamous cell carcinoma of the head and neck (SCCHN). [D] . Mburu, Yvonne K. 2011

机译：趋化因子受体7在头颈部转移性鳞状细胞癌（SCCHN）中表达的炎症机制。
7. Cost-effectiveness of pembrolizumab for treatment of platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma in China: an economic analysis based on a randomised open-label phase III trial [O] . Wenxiu Xin, Haiying Ding, Qilu Fang, 2020

机译：Pembrolizuab用于治疗中国铂抗性或转移性头部和颈鳞状细胞癌的成本效果：基于随机开放标签第三阶段试验的经济分析
8. A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer [O] . Cristina P. Rodriguez, Qian (Vicky) Wu, Jenna Voutsinas, 2019

机译：彭布罗鲁瑞司和副转移头和颈鳞状细胞癌和唾液腺癌中的II期试验

A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer

摘要

著录项

相似文献

相关主题

期刊订阅